A Phase 3 Single-arm Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
Conditions: Bladder Cancer; Urothelial Carcinoma; Urothelial Carcinoma Bladder Interventions: Drug: UGN-103 Sponsors: UroGen Pharma Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Pharmaceuticals | Research | Study